PropThink: Pozen Presents Impressive Phase 3 Data At ACG

[ACN Newswire] – By Jason Napodano, CFAOn October 22, 2012, Pozen (NASDAQ:POZN) presented a full analysis of the integrated results of its two Phase 3 studies comparing PA-325/40 (EC-ASA 325 mg + IR omeprazole 40 mg) to … more

View todays social media effects on AZN

View the latest stocks trending across Twitter. Click to view dashboard